Grifols, S.A.

GRF

ES0171996087

Pharmaceuticals

Real-time Estimate Tradegate Other stock markets 05:27:28 20/05/2024 pm IST			5-day change	1st Jan Change
9.987 ^EUR	+1.02%		+1.96%	-35.35%

17/05	European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Friday Trading	MT
15/05	GRIFOLS : In line Q1 and on track deleveraging; worth a go

Grifols CEO to become non-executive chairman in 2025

February 29, 2024 at 07:10 pm IST

BARCELONA, Feb 29 (Reuters) - The current chief executive and executive chairman of Spanish drug maker Grifols Thomas Glanzmann, who is due to leave as CEO and remain executive chairman on April 1, said on Thursday he will become the company's non-executive chairman in 2025. (Reporting by Joan Faus; Writing by David Latona; Editing by)

Latest news about Grifols, S.A.

European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Friday Trading	17/05	MT
GRIFOLS : In line Q1 and on track deleveraging; worth a go	15/05
Grifols, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
Grifols swings to first-quarter profit, says guidance on track	14/05	RE
Grifols' CFO Alfredo Arroyo Will Leave Company Next Year	14/05	RE
GRIFOLS' CFO ALFREDO ARROYO WILL LEAVE COMPANY NEXT Y…	14/05	RE
Grifols posts first-quarter profit of 21 million euros	14/05	RE
GRIFOLS CEO SAYS CAN CONFIRM SHANGHAI RAAS TRANSACTION WILL CLO…	14/05	RE
Transcript : Grifols, S.A., Q1 2024 Earnings Call, May 14, 2024	14/05
Spain's Grifols swings to first-quarter profit of 21 mln euros	14/05	RE
Grifols shares fall after new Gotham City Research report	14/05	RE
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher	13/05	MT
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	09/05	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading	08/05	MT
Sector Update: Health Care Stocks Advance in Monday Afternoon Trading	06/05	MT
Grifols Shares Rise as Haier Deal Set to Close in June	06/05	MT
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	06/05	MT
Grifols Expects June Completion of Haier Group Deal	06/05	MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower	03/05	MT
European Equities Traded in the US as American Depositary Receipts Rise Modestly Higher in Thursday Trading	02/05	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Lower in Wednesday Trading	01/05	MT
Grifols Issues EUR1 Billion Notes Due 2030	30/04	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday Trading	29/04	MT
European Equities Traded in the US as American Depositary Receipts Jump in Tuesday Trading	23/04	MT
Grifols to Launch EUR1 Billion Note Offering	23/04	MT

Chart Grifols, S.A.

Duration

Period

More charts

Company Profile

Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows: - products derived from plasma (84.3%): products for use by the pharmaceutical and biotechnology industries; - diagnostic machines and reagents (10.2%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers; - hospital products (2.4%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies; - other (3.1%): primarily intermediate biological products and subcontracted manufacturing services. Net sales are distributed geographically as follows: Spain (5.5%), European Union (13.6%), the United States and Canada (59.1%) and other (21.8%).

Sector

Pharmaceuticals

Calendar

25/07/2024 - Q2 2024 Earnings Release (Projected)

Related indices

STOXX EUROPE 600 (EUR) , IBEX 35

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

GRIFOLS : In line Q1 and on track deleveraging; worth a go

May 15, 2024 at 05:24 pm IST

Gotham City sets its sights on Grifols

January 09, 2024 at 08:39 pm IST

More Strategies

Ratings for Grifols, S.A.

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

9.886 EUR

Average target price

16.81 EUR

Spread / Average Target

+70.01%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
GRIFOLS, S.A.	-35.35%	643.97Cr
CSL LIMITED	-3.05%	9.04TCr
SAMSUNG BIOLOGICS CO.,LTD.	+3.68%	4.14TCr
BIOGEN INC.	-10.90%	3.36TCr
UCB	+60.01%	2.57TCr
BIOMARIN PHARMACEUTICAL INC.	-19.56%	1.47TCr
INCYTE CORPORATION	-9.06%	1.28TCr
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.34%	1.17TCr
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.53%	1.14TCr
SWEDISH ORPHAN BIOVITRUM AB	+5.02%	879.22Cr

Biopharmaceuticals

Grifols, S.A.

Equities

GRF

ES0171996087

Pharmaceuticals

Grifols CEO to become non-executive chairman in 2025

EPS Revisions